These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 17392010

  • 1. [Hormone replacement therapy in postmenopausal women: all the treatments are not the same].
    Ribot C, Trémollieres F.
    Gynecol Obstet Fertil; 2007 May; 35(5):388-97. PubMed ID: 17392010
    [Abstract] [Full Text] [Related]

  • 2. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M, Simoncini T, Fuller S, Genazzani AR.
    Maturitas; 2008 May; 60(3-4):185-201. PubMed ID: 18775609
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract] [Full Text] [Related]

  • 7. [Hormone replacement therapy in postmenopausal women: all the treatments are not the same. Do all the patients have the same characteristics?].
    Mathelin C, Brettes JP.
    Gynecol Obstet Fertil; 2007 Jun; 35(6):502-3. PubMed ID: 17543563
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The rationale for a wider range of progestogens.
    Skouby SO.
    Climacteric; 2000 Dec; 3 Suppl 2():14-20. PubMed ID: 11379382
    [Abstract] [Full Text] [Related]

  • 10. [Hormone replacement therapy in postmenopausal women and breast cancer risk: impact of estrogens deprivation and timing hypothesis].
    Brettes JP, Mathelin C.
    Gynecol Obstet Fertil; 2007 Nov; 35(11):1092-4. PubMed ID: 17996474
    [No Abstract] [Full Text] [Related]

  • 11. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T, Genazzani AR.
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Postmenopausal hormone therapy and risk of breast cancer.
    Chen FP.
    Chang Gung Med J; 2009 Feb; 32(2):140-7. PubMed ID: 19403003
    [Abstract] [Full Text] [Related]

  • 14. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G.
    Rep Med Guidel Outcomes Res; 2002 Aug 09; 13(15):5-7. PubMed ID: 12553323
    [No Abstract] [Full Text] [Related]

  • 15. [Postmenopausal hormone therapy--an update. Benefit versus risk--important to identify women with increased breast cancer risk].
    von Schoultz B.
    Lakartidningen; 2002 Aug 09; 106(34):2041-2. PubMed ID: 19769143
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Postmenopausal hormone therapy and breast cancer: what is the problem?
    Kenemans P.
    Maturitas; 2005 May 16; 51(1):75-82. PubMed ID: 15883112
    [Abstract] [Full Text] [Related]

  • 19. [Hormone therapy and risk for breast cancer in Finnish postmenopausal women].
    Lyytinen H, Ylikorkala O.
    Duodecim; 2011 May 16; 127(3):235-42. PubMed ID: 21438346
    [Abstract] [Full Text] [Related]

  • 20. Where are we with postmenopausal hormone therapy in 2005?
    Lam PM, Chung TK, Haines C.
    Gynecol Endocrinol; 2005 Nov 16; 21(5):248-56. PubMed ID: 16373243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.